Global Beta-thalassemia (B-thal) Market Research Report 2021-2028 |Key Players, Growth Analysis, Share, Global Trends

Beta-thalassemia (B-thal) Market Report highlights the following key takeaways:

Beta-thalassemia (B-thal) Market Report highlights the following key takeaways:

  • The iron-chelating agents appear to be in charge of the Beta-Thalassemia market outlook.
  • Exjade is the first commercially available once-daily oral iron chelator for the treatment of chronic transfusional iron excess caused by a variety of underlying anemias.
  • To eliminate the disease's lifetime burden, the Beta-Thalassemia industry is seeing an infusion of gene treatments and gene-edited cell therapies.
  • Several new medications, including LentiGlobin, are being considered for or have already gained Orphan Drug Designation.
  • Bluebird Bio, Protagonist Therapeutics, Acceleron Pharma, Agios Pharmaceuticals, Ionis Pharmaceuticals, and other key pharma players are dynamically pushing the Beta-thalassemia (B-thal) Market size.
  • ZYNTEGLO (LentiGlobin BB305), Sotatercept (ACE-011), Mitapivat (AG-348), PTG-300, IONIS-TMPRSS6-LRx, VIT-2763, Emeramide, and several more medicines are expected to revolutionize the Beta-Thalassemia market landscape.
The global prevalence of Beta-Thalassemia is increasing due to increased rates of human migration, the launch of novel and cutting-edge therapies, improvements in diagnostic techniques, patient involvement, major healthcare providers' involvement, and governmental programmes leading to increased awareness, high-priced gene therapies, and an increase in R&D activities since the cloning of the Beta–globin gene.

Beta-thalassemia is a rare genetic condition that is passed down through the generations in an autosomal recessive pattern. The absence of haemoglobin in RBCs is the predominant symptom of the disease, which is caused by mutations in the HBB gene on chromosome 11. The severity of Beta-Thalassemia is determined by the type of mutation and whether or not mutations are present in one or both alleles.

Patients with Beta-Thalassemia can be divided into two categories based on their need for blood transfusions: transfusion-dependent thalassemia (TDT) and non-transfusion dependent thalassemia (NTDT) (NTDT).

Epidemiological Study of Beta-Thalassemia

In 2020, the overall Beta-Thalassemia prevalent population in the 6MM was 14,954, according to DelveInsight. Italy had the most prevalence of Beta-Thalassemia patients, followed by the United States, while Spain had the smallest prevalence of Beta-Thalassemia patients.

Comments